Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study

Guardado en:

Detalles Bibliográficos
Autores principales:	Yuliya Lytvyn, PhD, Asfandyar Mufti, MD, Hiba Zaaroura, MD, Muskaan Sachdeva, BHSc, Justin D. Lu, MSc, Brian D. Rankin, PhD, Vimal H. Prajapati, MD, Ronald Vender, MD, Jensen Yeung, MD, FRCPC
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	biologic efficacy IL-23 inhibitor psoriasis risankizumab Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/e5569883aea8428a970c97f32babd322
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e5569883aea8428a970c97f32babd322
record_format	dspace
spelling	oai:doaj.org-article:e5569883aea8428a970c97f32babd3222021-11-12T04:47:55ZEfficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study2666-328710.1016/j.jdin.2021.09.007https://doaj.org/article/e5569883aea8428a970c97f32babd3222022-03-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666328721000766https://doaj.org/toc/2666-3287Yuliya Lytvyn, PhDAsfandyar Mufti, MDHiba Zaaroura, MDMuskaan Sachdeva, BHScJustin D. Lu, MScBrian D. Rankin, PhDVimal H. Prajapati, MDRonald Vender, MDJensen Yeung, MD, FRCPCElsevierarticlebiologicefficacyIL-23inhibitorpsoriasisrisankizumabDermatologyRL1-803ENJAAD International, Vol 6, Iss , Pp 3-5 (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	biologic efficacy IL-23 inhibitor psoriasis risankizumab Dermatology RL1-803
spellingShingle	biologic efficacy IL-23 inhibitor psoriasis risankizumab Dermatology RL1-803 Yuliya Lytvyn, PhD Asfandyar Mufti, MD Hiba Zaaroura, MD Muskaan Sachdeva, BHSc Justin D. Lu, MSc Brian D. Rankin, PhD Vimal H. Prajapati, MD Ronald Vender, MD Jensen Yeung, MD, FRCPC Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
format	article
author	Yuliya Lytvyn, PhD Asfandyar Mufti, MD Hiba Zaaroura, MD Muskaan Sachdeva, BHSc Justin D. Lu, MSc Brian D. Rankin, PhD Vimal H. Prajapati, MD Ronald Vender, MD Jensen Yeung, MD, FRCPC
author_facet	Yuliya Lytvyn, PhD Asfandyar Mufti, MD Hiba Zaaroura, MD Muskaan Sachdeva, BHSc Justin D. Lu, MSc Brian D. Rankin, PhD Vimal H. Prajapati, MD Ronald Vender, MD Jensen Yeung, MD, FRCPC
author_sort	Yuliya Lytvyn, PhD
title	Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
title_short	Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
title_full	Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
title_fullStr	Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
title_full_unstemmed	Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
title_sort	efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: a 16-week canadian retrospective multicenter cohort study
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/e5569883aea8428a970c97f32babd322
work_keys_str_mv	AT yuliyalytvynphd efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy AT asfandyarmuftimd efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy AT hibazaarouramd efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy AT muskaansachdevabhsc efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy AT justindlumsc efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy AT briandrankinphd efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy AT vimalhprajapatimd efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy AT ronaldvendermd efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy AT jensenyeungmdfrcpc efficacyandsafetyofrisankizumabformoderatetosevereplaquepsoriasisinclinicalpracticea16weekcanadianretrospectivemulticentercohortstudy
_version_	1718431261477830656

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study

Ejemplares similares